Puma Biotechnology

PBYI

Market cap $287M

Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.

Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript

Puma Biotech (PBYI) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 4Q-2025 earnings release on Feb. 26 and followed with a conference call to review results.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO & President Alan Auerbach will provide a corporate overview at the TD Cowen Health Care Conference on March 2 at 2:30 pm ET.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its fourth quarter and full year 2025 results, followed be a conference call, after the close on Feb. 26, 2026.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the grant of inducement awards to two new hires in January 2026, as required under Nasdaq Listing Rule 5635(c)(4).

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted to December 2025 new hires, in accordance with Nasdaq Listing Rule 5635(c)(4).

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology was added to the Nasdaq Biotechnology Index effective after the close of trading on Dec. 19, 2025.

CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.